echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Breast cancer patients with PALB2 embryo mutations can also benefit from PARPi treatment

    J Clin Oncol: Breast cancer patients with PALB2 embryo mutations can also benefit from PARPi treatment

    • Last Update: 2020-11-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    PARP inhibitor (PARPi) Olaparib has been approved for the treatment of HER2-negative metastasis breast cancer (MBC) with BRCA1/2 embryoline (germline, g) mutations.
    whether Olapali can be used in MPC patients carrying BRCA1/2 system (somatic, s) mutations or other HR-related gene g/s mutations other than BRCA1/2 is unclear.
    study is an Extended Phase II Olapali study designed to assess the efficacy of Olapa in patients with the above-mentioned MPC.
    recruit MVC patients who carry HR-related gene germ line mutations (queue 1) other than BRCA1/2, or THOSE-related gene (including BRCA1/2) system mutations (queue 2).
    requires that patients have not been treated with PARPi in the past, non-platinum resusable diseases or past chemotherapy after progressing no more than twice.
    Olapali 300 mg orthopaedia (2/day) until the disease progresses.
    end points are objective mitigation rates (ORRs), and secondary endpoints include clinical benefit rates and progression-free survival (PFS).
    recruited a total of 54 patients.
    76% of patients were ER-positive and HER2-negative.
    87% of patients carry PALB2, sBRCA1/2, ATM or CHEK2 mutations.
    in queue 1, ORR is 33%, and in queue 2, ORR bit is 31%.
    patients with only gPALB2 and sBRCA1/2 mutations were relieved (ORR was 82% and 50%, respectively).
    13.3 months for patients with gPALB2 and 6.3 months for patients with sBRCA1/2 mutations.
    patients with only ATM or CHEK2 mutations did not see remission.
    PARP inhibition can effectively treat MPC patients with gPALB2 or SBRCA/2 mutations, greatly expanding the population of breast cancer patients who may benefit from PARPi therapy.
    the results emphasize the value of molecular properties in MPC treatment decisions.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.